Physician profile
Jane L Meisel
NPI 1831358076
$83,476.14
in general payments reported to CMS, 2019-2025
21 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $8,172 · 2021: $15K · 2022: $13K · 2023: $5,709 · 2024: $15K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Travel and Lodging: $1,317 · Honoraria: $1,260 · Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,520.00 |
| Travel and Lodging | $1,317.34 |
| Honoraria | $1,260.00 |
| Food and Beverage | $562.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23,530.47 | 2021-2025 | Enhertu, Truqap |
| Pfizer INC. | $14,413.27 | 2019-2025 | |
| Puma Biotechnology, INC. | $11,901.80 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $7,364.79 | 2020-2024 | |
| Seagen INC. | $5,520.00 | 2021-2022 | |
| Astrazeneca Uk Limited | $4,795.00 | 2024-2025 | |
| Genzyme Corporation | $3,313.69 | 2021-2022 | |
| Gilead Sciences, INC. | $3,181.92 | 2021-2022 | |
| Eli Lilly and Company | $3,162.50 | 2020 | |
| Stemline Therapeutics INC. | $1,950.00 | 2024 | Orserdu |
| Glaxosmithkline, LLC. | $1,950.00 | 2021 | |
| Clovis Oncology, INC. | $1,500.00 | 2020 | |
| Genentech USA, INC. | $825.00 | 2021 | |
| Biogen, INC. | $43.76 | 2020 | |
| Tesaro, INC. | $23.94 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Meisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.